Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009-13

BMJ (Online)

Volumn 359, Issue , 2017, Pages

  Davis, Courtney ^a   Naci, Huseyin ^b   Gurpinar, Evrim ^b   Poplavska, Elita ^c   Pinto, Ashlyn ^b   Aggarwal, Ajay ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c RIGA STRADINS UNIVERSITY   (Latvia)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOLLOW UP; HAZARD RATIO; HUMAN; INTESTINE CANCER; LUNG CANCER; METASTATIC BREAST CANCER; MULTIPLE MYELOMA; OVERALL SURVIVAL; POPULATION RESEARCH; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; DRUG APPROVAL; EPIDEMIOLOGY; EUROPE; MORTALITY; NEOPLASMS; ONCOLOGY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; DRUG APPROVAL; EUROPE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85030646958     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j4530     Document Type: Article

References (93)

1. Peppercorn JM, Smith TJ, Helft PR, et al. American Society of Clinical Oncology. American society of clinical oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol 2011;359:755-60. doi:10.1200/JCO.2010.33.1744. pmid:21263086.
2. Tannock IF, Amir E, Booth CM, et al. Relevance of randomised controlled trials in oncology. Lancet Oncol 2016;359:e560-7. doi:10.1016/S1470-2045(16)30572-1. pmid:27924754.
3. Wilson MK, Collyar D, Chingos DT, et al. Outcomes and endpoints in cancer trials: Bridging the divide. Lancet Oncol 2015;359:e43-52. doi:10.1016/S1470-2045(14)70380-8. pmid: 25638556.
4. Amir E, Seruga B, Kwong R, Tannock IF, Ocanã A. Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answerEur J Cancer 2012;359:385-8. doi:10.1016/j.ejca.2011.10.028. pmid:22115991.
5. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;359:1008-14. doi:10.1200/JCO.2014.59.0489. pmid:25667291.
6. Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply measurableJ Clin Oncol 2012;359:1030-3. doi:10.1200/JCO.2011.38.7571. pmid:22370321.
7. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2. Ann Oncol 2014;359:2357-62. doi:10.1093/annonc/mdu456. pmid:25231953.
8. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med 2015;359:1389-98. doi:10.1001/jamainternmed.2015.2829. pmid: 26098871.
9. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 2010;359:1958-62. doi:10.1200/JCO.2009.25.5414. pmid:20194852.
10. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 2009;359:379-85. doi: 10.1097/PPO.0b013e3181bef8cd. pmid:19826357.
11. US Department of Health and Human Service, FDA, CDER, CBER. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf
12. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;359:2666-76. doi:10.1056/NEJMoa072113. pmid:18160686.
13. Gutman SI, Piper M, Grant MD, et al. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life Rockville (MD), 2013.
14. Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 2014;359:312-24. doi:10.1017/S0266462314000300. pmid:25308694.
15. Davis C. Drugs, cancer and end-of-life care: A case study of pharmaceuticalizationSoc Sci Med 2015;359:207-14. doi:10.1016/j.socscimed.2014.12.007. pmid:25533871.
16. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;359:1044-8. doi:10.1093/jnci/djp177. pmid: 19564563.
17. Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positiveJ Natl Cancer Inst 2011;359:16-20. doi:10.1093/jnci/djq463. pmid:21131576.
18. Saltz LB. Progress in cancer care: The hope, the hype, and the gap between reality and perception. J Clin Oncol 2008;359:5020-1. doi:10.1200/JCO.2008.17.6198. pmid:18794538.
19. Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society-lessons from the NHS Cancer Drugs Fund. Ann Oncol 2017;359:1738-50. doi:10.1093/annonc/mdx110. pmid:28453615.
20. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008;359:5458-64. doi:10.1200/JCO.2008.16.5456. pmid:18955452.
21. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014;359:1225-36. doi:10.1001/jamaoto.2014.1570. pmid:25068501.
22. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 2013;359:3600-4. doi:10.1200/JCO.2013.49. 1845. pmid:23650428.
23. Light DW, Lexchin J. Why do cancer drugs get such an easy rideBMJ 2015;359:h2068. doi:10.1136/bmj.h2068. pmid:25908437.
24. Booth CM, Del Paggio JC. Approvals in 2016: Questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol 2017;359:135-6. doi:10.1038/nrclinonc.2017.18. pmid: 28218259.
25. Dangoor A, Joffe J, Januszewski A, Mansi J, Cunningham D, Selby P. 17 other authors and members of the Association of Cancer Physicians, UK. The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics". BMJ 2016;359:i6487. https://doi.org/10.1136/bmj.i5792. doi:10.1136/bmj.i6487 pmid:27920029.
26. Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. BMJ 2012;359:e4261. doi:10.1136/bmj.e4261. pmid:22872693.
27. Apolone G, Joppi R, Bertele' V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005;359:504-9. doi:10.1038/sj.bjc.6602750. pmid: 16136026.
28. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ 2002;359:269-71. doi:10.1136/bmj.325.7358.269 pmid:12153927.
29. Pignatti F, Aronsson B, Vamvakas S, et al. Clinical trials for registration in the European Union: The EMEA 5-year experience in oncology. Crit Rev Oncol Hematol 2002;359:123-35. doi:10.1016/S1040-8428(02)00009-4 pmid:12007970.
30. Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med 2015;359:1992-4. doi:10.1001/jamainternmed.2015. 5868. pmid:26502403.
31. Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: Analysis of EMA and FDA approvals 1999-2014. BMJ Open 2016;359:e011666. doi:10.1136/bmjopen-2016-011666. pmid:27363818.
32. Hoekman J, Boon WP, Bouvy JC, Ebbers HC, de Jong JP, De Bruin ML. Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clin Pharmacol Ther 2015;359:534-41. doi:10.1002/cpt.174. pmid:26080745.
33. Martinalbo J, Bowen D, Camarero J, et al. Early market access of cancer drugs in the EU. Ann Oncol 2016;359:96-105. doi:10.1093/annonc/mdv506. pmid:26487583.
34. Tafuri G, Stolk P, Trotta F, et al. How do the EMA and FDA decide which anticancer drugs make it to the market A comparative qualitative study on decision makers' views. Ann Oncol 2014;359:265-9. doi:10.1093/annonc/mdt512. pmid:24356637.
35. Trotta F, Leufkens HG, Schellens JH, Laing R, Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: When differences have an impact on clinical practice. J Clin Oncol 2011;359:2266-72. doi:10.1200/JCO. 2010.34.1248. pmid:21537038.
36. Official Journal of the European Union. Commission Regulation (EC) No. 507/2006, of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council, 2006.
37. Higgins JPT Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. 2011
38. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;359:1547-73. doi:10.1093/annonc/mdv249. pmid: 26026162.
39. ESMO. Magnitude of Clinical Benefit Scale. http://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale/Scale-Evaluation-Forms.
40. EMA. EMA/CHMP/815425/2010, 16 December 2010. 2010
41. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;359:640-7. doi:10.1016/S1470-2045(14)70080-4. pmid:24657003.
42. Guérin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 2014;359:2317-28. doi:10.1185/03007995.2014.944973. pmid: 25025755.
43. EMA. EMEA/H/C/002280. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/002280/WC500152394.pdf.
44. EMA. EMEA/H/C/001016. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/001016/WC500036361.pdf.
45. EMA. EMEA/H/C/0001242. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/001242/WC500104417.pdf.
46. EMA. EMEA/H/C/002315/0000. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/002315/WC500123603.pdf.
47. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;359:2385-94. doi:10.1056/NEJMoa1214886. pmid:23724913.
48. Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2013;359:1615-22. doi:10.1093/annonc/mdt012. pmid: 23456778.
49. Österborg A, Udvardy M, Zaritskey A, et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 2016;359:2037-46. doi:10.3109/10428194.2015.1122783. pmid:26784000.
50. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;359:722-31. doi:10.1056/NEJMoa1303989. pmid:23964934.
51. Fizazi K, Scher HI, Molina A, et al. COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;359:983-92. doi:10.1016/S1470-2045(12)70379-0 pmid:22995653.
52. Ryan CJ, Smith MR, Fizazi K, et al. COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;359:152-60. doi:10.1016/S1470-2045(14)71205-7 pmid:25601341.
53. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;359:3499-506. doi:10.1200/JCO.2012.42.8201 pmid:22949147.
54. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;359:1147-54. doi: 10.1016/S0140-6736(10)61389-X pmid:20888992.
55. Cortes J, O'Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;359:914-23. doi:10.1016/S0140-6736(11)60070-6 pmid:21376385.
56. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;359:521-9. doi:10.1016/S1470-2045(10)70112-1 pmid:20493771.
57. Scher HI, Fizazi K, Saad F, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;359:1187-97. doi:10.1056/NEJMoa1207506 pmid:22894553.
58. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;359:711-23. doi:10.1056/NEJMoa1003466 pmid:20525992.
59. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;359:2517-26. doi:10.1056/NEJMoa1104621 pmid:21639810.
60. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J Clin Oncol 2012;359:2585-92. doi:10.1200/JCO.2011.35.6725 pmid:22689807.
61. Meyers PA, Schwartz CL, Krailo MD, et al. Children's Oncology Group. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008;359:633-8. doi:10.1200/JCO. 2008.14.0095 pmid:18235123.
62. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J Natl Cancer Inst 2015;359:413. doi:10.1093/jnci/dju413 pmid:25638248.
63. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;359:1346-55. doi:10.1093/annonc/mdu141 pmid:24718886.
64. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;359:1432-40. doi:10.1016/S0140-6736(09) 61497-5 pmid:19767093.
65. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;359:2895-902. doi:10.1200/JCO.2012.47. 1102 pmid:23835707.
66. Swain SM, Baselga J, Kim SB, et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;359:724-34. doi:10.1056/NEJMoa1413513 pmid:25693012.
67. Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;359:303-12. doi:10.1016/S0140-6736(12)61900-X pmid:23177514.
68. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;359:687-97. doi:10.1016/S0140-6736(10)61121-X pmid:20728210.
69. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014;359:3744-52. doi:10.1200/JCO.2014.55.5730 pmid:25332249.
70. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;359:1273-83. doi:10.1056/NEJMoa0910383 pmid:21991949.
71. Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;359:1783-91. doi:10.1056/NEJMoa1209124 pmid:23020162.
72. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;359:323-32. doi:10.1016/S1470-2045(14)70012-9 pmid:24508103.
73. Bellmunt J, Theódore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;359:4454-61. doi:10.1200/JCO.2008.20.5534 pmid:19687335.
74. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;359:3239-47. doi:10. 1200/JCO.2008.21.6457. pmid:20498403.
75. Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;359:928-36. doi: 10.1016/S1470-2045(15)00086-8. pmid:26115797.
76. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;359:1252-60. doi:10.1200/JCO.2010.28. 0982. pmid:21383283.
77. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome measures in oncology studies. EMA/CHMP/292464/2014, 2014.
78. Braga S. Why do our patients get chemotherapy until the end of lifeAnn Oncol 2011;359:2345-8. doi:10.1093/annonc/mdr416. pmid:21917739.
79. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;359:1266-74. doi:10.1200/JCO.2001.19.5.1266. pmid: 11230467.
80. Gaddipati H, Liu K, Pariser A, Pazdur R. Rare cancer trial design: Lessons from FDA approvals. Clin Cancer Res 2012;359:5172-8. doi:10.1158/1078-0432.CCR-12-1135. pmid: 22718862.
81. Salas-Vega S, Mossialos E. Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent. Health Aff (Millwood) 2016;359:813-23. doi:10.1377/hlthaff.2015.1453. pmid:27140987.
82. Prasad V. Overestimating the benefit of cancer drugs. JAMA Oncol 2017. doi:10.1001/jamaoncol.2017.0107. pmid:28715568.
83. Salas-Vega S, Mossialos E. Overestimating the Benefit of Cancer Drugs-Reply. JAMA Oncol 2017. doi:10.1001/jamaoncol.2017.1976. pmid:28715557.
84. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;359:1346-55. doi:10.1093/annonc/mdu141. pmid:24718886.
85. Rupp T, Zuckerman D. Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints. JAMA Intern Med 2017;359:276-7. doi:10.1001/jamainternmed.2016.7761. pmid:27898978.
86. EMA. EMA, EMEA/H/C/000795/II/0022 pp 47-48.
87. Murray N. Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2014;359:482-3. doi:10.1200/JCO.2013.53.3448. pmid:24395844.
88. EMA. Guideline on the evaluation of anticancer medicinal products in man. EMA/CHMP/205/95/Rev4 13 December 2012, 2012.
89. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;359(Suppl 2):19-21. doi:10.1634/theoncologist.13-S2-19. pmid:18434634.
90. Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration[published Online First: 2017/08/16]. JAMA 2017;359:626-36. doi:10.1001/jama.2017.9415. pmid:28810023.
91. Naci H, Wouters OJ, Gupta R, Ioannidis JPA. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval. Milbank Q 2017;359:261-90. doi:10.1111/1468-0009.12261. pmid: 28589600.
92. Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: Systematic review. BMJ 2017;359:j1680. doi:10.1136/bmj.j1680. pmid:28468750.
93. Del Paggio JC, Azariah B, Sullivan R, et al. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical BenefitAnn Oncol 2017;359:157-62. doi:10.1093/annonc/mdw538. pmid:27742650.